Surface Oncology, Inc. (NASDAQ:SURF – Get Rating) CEO Robert W. Ross sold 10,594 shares of the firm’s stock in a transaction that occurred on Wednesday, August 3rd. The stock was sold at an average price of $1.72, for a total transaction of $18,221.68. Following the completion of the transaction, the chief executive officer now directly owns 99,906 shares of the company’s stock, valued at $171,838.32. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Surface Oncology Price Performance
Shares of NASDAQ:SURF opened at $1.78 on Friday. The firm has a fifty day moving average price of $1.80 and a two-hundred day moving average price of $2.48. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.19 and a quick ratio of 9.42. Surface Oncology, Inc. has a one year low of $1.37 and a one year high of $8.38.
Surface Oncology (NASDAQ:SURF – Get Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of ($0.48) by $0.61. Surface Oncology had a negative net margin of 182.63% and a negative return on equity of 48.17%. The firm had revenue of $30.00 million during the quarter. As a group, equities analysts anticipate that Surface Oncology, Inc. will post -1.19 EPS for the current year.
Analysts Set New Price Targets
Institutional Trading of Surface Oncology
Institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new stake in shares of Surface Oncology during the 1st quarter valued at $27,000. Formidable Asset Management LLC purchased a new stake in shares of Surface Oncology during the 1st quarter valued at $33,000. Delphia USA Inc. purchased a new stake in shares of Surface Oncology during the 1st quarter valued at $36,000. Forefront Analytics LLC purchased a new stake in shares of Surface Oncology during the 1st quarter valued at $62,000. Finally, JPMorgan Chase & Co. raised its position in shares of Surface Oncology by 26.4% during the 1st quarter. JPMorgan Chase & Co. now owns 22,082 shares of the company’s stock valued at $65,000 after buying an additional 4,611 shares in the last quarter. Hedge funds and other institutional investors own 70.81% of the company’s stock.
About Surface Oncology
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8.
- Get a free copy of the StockNews.com research report on Surface Oncology (SURF)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.